Skip to main content

Table 2 The predicted T cytotoxic cells epitopes, their antigenicity, allergenicity, toxicity and the population coverage from spike S protein and orf1ab polyprotein

From: Vaccinomic approach for novel multi epitopes vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)

Protein Epitopes Start End Vaxijen antigenicity (0.4) Allergenicity Toxicity Population coverage
Spike S protein FTISVTTEI 718 726 0.8535 Nonallergen Nontoxin 52.54%
FVFLVLLPL 2 10 0.8601 Nonallergen Nontoxin 48.45%
VVFLHVTYV 1060 1068 1.5122 Nonallergen Nontoxin 48.45%
VRFPNITNL 327 335 1.1141 Nonallergen Nontoxin 41.68%
aFAMQMAYRF 898 906 1.0278 Nonallergen Nontoxin 39.96%
orf1ab aVMYASAVVL 3683 3691 0.4778 Nonallergen Nontoxin 57.06%
SLIYSTAAL 2242 2250 0.452 Nonallergen Nontoxin 51.80%
MMISAGFSL 6425 6433 1.0248 Nonallergen Nontoxin 51.47%
FVMMSAPPA 1804 1812 0.4871 Nonallergen Nontoxin 48.97%
FLLNKEMYL 3183 3191 0.44 Nonallergen Nontoxin 45.42%
aFLLPSLATV 3639 3647 0.5954 Nonallergen Nontoxin 40.60%
aSLENVAFNV 6453 6461 1.0488 Nonallergen Nontoxin 40.60%
  1. athe overlapped epitopes between MHCI and MHCII molecules were used once in the vaccine construct as MHCI or MHCII epitopes